MetaVia Inc., a clinical-stage biotechnology company, has announced the dosing of the first patient in the 48 mg multiple ascending dose cohort of its Phase 1 clinical trial for DA-1726, a dual oxyntomodulin analog agonist designed for obesity treatment. This trial aims to explore the maximum tolerated dose of DA-1726, which functions as both a glucagon-like peptide-1 receptor and glucagon receptor agonist. Previous data from the 32 mg dose has indicated potential therapeutic benefits, such as dose-dependent weight loss and waist reduction, without inducing hypoglycemia. The drug has also demonstrated favorable cardiovascular safety and tolerability profiles. MetaVia expects to present the top-line data from the 48 mg cohort in the fourth quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.